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Abstract
Background: This study presents an empirical investigation of the ethical reasoning and ethical issues at stake in
the daily work of physicians and molecular biologists in Denmark. The aim of this study was to test empirically
whether there is a difference in ethical considerations and principles between Danish physicians and Danish
molecular biologists, and whether the bioethical principles of the American bioethicists Tom L. Beauchamp and
James F. Childress are applicable to these groups.
Method: This study is based on 12 semi-structured interviews with three groups of respondents: a group of
oncology physicians working in a clinic at a public hospital and two groups of molecular biologists conducting basic
research, one group employed at a public university and the other in a private biopharmaceutical company.
Results: In this sample, the authors found that oncology physicians and molecular biologists employed in a private
biopharmaceutical company have the specific principle of beneficence in mind in their daily work. Both groups are
motivated to help sick patients. According to the study, molecular biologists explicitly consider nonmaleficence
in relation to the environment, the researchers' own health, and animal models; and only implicitly in relation to
patients or human subjects. In contrast, considerations of nonmaleficence by oncology physicians relate to
patients or human subjects. Physicians and molecular biologists both consider the principle of respect for
autonomy as a negative obligation in the sense that informed consent of patients should be respected. However,
in contrast to molecular biologists, physicians experience the principle of respect for autonomy as a positive
obligation as the physician, in dialogue with the patient, offers a medical prognosis based upon the patients wishes
and ideas, mutual understanding, and respect. Finally, this study discloses utilitarian characteristics in the overall
conception of justice as conceived by oncology physicians and molecular biologists from the private
biopharmaceutical company. Molecular biologists employed at a public university are, in this study, concerned
with allocation, however, they do not propose a specific theory of justice.
Conclusion: This study demonstrates that each of the four bioethical principles of the American bioethicists
Tom L. Beauchamp & James F. Childress – respect for autonomy, beneficence, nonmaleficence and justice – are
reflected in the daily work of physicians and molecular biologists in Denmark. Consequently, these principles are
applicable in the Danish biomedical setting.
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Introduction
Developing a suitable method
The basic approach of biomedical ethics has primarily
been philosophical inquiry with the aim of logical reason-
ing, conceptual clarity, coherence and rational justifica-
tion [1]. Although such theoretical reflections make
important contributions to the field, empirical researchers
regard some of these attempts as remote from biomedical
practice [2]. On the other hand, published empirical
research on the ethical reasoning of nurses and physicians
offers only descriptions of such reasoning. For instance,
Lindseth & Norberg [3] developed a phenomenological
hermeneutical method to reveal the morals and the ethi-
cal thinking of physicians and nurses based on interviews.
According to Lindseth & Norberg [3] this method can be
used to elucidate the essential understandable meaning of
good and bad as actually lived in human experience. The
method was inspired by Husserl's descriptive phenome-
nology in as much as the aim is to describe the lived expe-
rience of the interviewees. It is essential that the researcher
has a phenomenological attitude, and sheds all prior per-
sonal knowledge to grasp the essential lived experience of
the respondents [4]. Furthermore, it is important that the
respondents shift to the phenomenological attitude, i.e.
refrain from making judgements about the factual.
According to Lindseth & Norberg [3]: "The easiest and, so
to speak, the natural way of doing this is to narrate from
lived experience". The approach is hermeneutical since
the task is to understand the experiences expressed in the
interview texts. Hermeneutics goes beyond the descrip-
tion of core concepts and essences to look for meanings
embedded in life practices. These meanings are not always
apparent to the respondents, but can be gleaned from the
narratives (the interview texts) they produce [4]. Udén et
al. [5] conducted a study using the phenomenological
hermeneutical method of Lindseth & Norberg [3] to
investigate the reflections of nurses and physicians in their
narratives about ethically difficult care episodes. Udén et
al. [5] concluded that the ethical thinking of nurses
appears to be related to the ethics of care, whereas the eth-
ical thinking of physicians is related to the ethics of jus-
tice. Moreover, the study [6] shows that nurses tell their
stories within a relationship ethics perspective and that
physicians tell their stories within an action ethics per-
spective. It remains unclear, however, whether nurses
ought to assume a care or relationship ethics perspective,
or if physicians ought to take a justice or action ethics per-
spective. Can the descriptive conclusions of the study have
any normative implications for nurses and physicians?
For instance, if an empirical study concludes that physi-
cians adhere to a paternalistic doctor-patient relationship
in which physicians do not respect the autonomy of the
patient, does such a study then imply that physicians
ought to adhere to such a paternalistic relationship? So the
question remains whether there is any relationship
between empirical findings and ethical theory about what
principles (appendix, note 1) we ought to act in accordance
with.
The results of the phenomenological hermeneutical
method of Lindseth & Norberg [3] are descriptive in as
much as they describe the lived experience of the respond-
ents. In Ebbesen & Pedersen [7] we argue that the phe-
nomenological hermeneutical method can be combined
with the moral philosophical method of Wide Reflective
Equilibrium (WRE) as a decision procedure for the formu-
lation of normative principles, because WRE is a method
or process of deciding what we should think, not merely
one of describing what we do think [8]. So to achieve a
normative approach, we combine the phenomenological
hermeneutical method with the method of WRE.
The method of WRE is based upon the American philoso-
pher John Rawls' theory for developing and justifying
principles for a just society. Rawls speaks of a system with
three levels: particular moral judgements, first principles,
and general convictions. He claims that particular moral
judgements are justified by the overall coherence (appen-
dix, note 2) of the system and uses the term WRE to
describe this state [9]. To achieve WRE, we start with our
initial moral judgments. We begin by screening our initial
moral judgements to eliminate those in which we have lit-
tle confidence and those made under circumstances con-
ducive to error. We then search for general moral
principles that best account for the remaining considered
moral judgements. We may find reason to revise or dis-
card some of our considered moral judgments that con-
flict with highly plausible moral principles. Rawls
imagines that the process of comparing principles with
our considered judgments will lead us to go back and
forth, sometimes modifying our principles and some-
times our considered moral judgements until the princi-
ples match, fit, or are in line with our considered moral
judgements and consistency is achieved. Finally, we have
to subject the moral principles we arrive at to alternative
moral perspectives and the force of various arguments for
these. WRE is achieved when our considered judgements
match, or are in line with our general principles duly
pruned and adjusted. However, this WRE is not necessar-
ily stable. For instance, it may be liable to be upset by par-
ticular cases which lead us to revise our judgments or
principles [9,10]. Moreover, the notions of 'match', 'fit',
'in line with' and 'consistency' are not well-defined. We
understand the terms as meaning that WRE requires logi-
cal consistency between considered moral judgements
and moral principles. Rawls writes that the justification of
ethical principles "is a matter of the mutual support of
many considerations, of everything fitting together into
one coherent view" [10]. Rawls believes that if reasonable
principles exist for deciding moral questions "there is aPhilosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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presumption that the principles of a satisfactory explica-
tion of the total range of the considered judgments of com-
petent judges (appendix, note 3) will at least approximate
them" [11].
In the light of an interpretation of the method of WRE as
a decision procedure, the purpose of this empirical study
is to validate, formulate and justify reasonable moral prin-
ciples in specific biomedical practice. To make the
approach normative, the interview guide was constructed
in accordance with the theory of WRE so that the respond-
ents could achieve WRE. For more details, please see
Ebbesen & Pedersen [7]. By combining the phenomeno-
logical hermeneutical method with WRE as a decision
procedure, we have an approach to bioethics where
empirical research is integrated into the formulation of
normative ethical principles, which means that the con-
clusions of this empirical study may provide health care
professionals and biomedical researchers with normative
principles about how to analyse, reason and act in practice
in ethically difficult situations.
Studying ethical reasoning of physicians and molecular 
biologists
Most qualitative empirical research in the field of biomed-
ical ethics is concerned with the ethical reasoning of phy-
sicians and nurses [5,6,12-15]. Some researchers have
been especially interested in studying differences in ethi-
cal reasoning between physicians and nurses, and
between men and women [5,6,13]. Others have specifi-
cally investigated how physicians handle situations in
which there is tension between the obligation to respect
the patients' right to autonomy and the obligation to pro-
mote their health [14,15]. However, little is known about
the differences in the ethical considerations at stake
between physicians working in the clinical situation and
molecular biologists conducting basic research.
This article presents partial findings from the larger
research project 'Bioethics in Theory and Practice', in
which our overall aim was to investigate the ethical rea-
soning of physicians and molecular biologists. We have
three groups of respondents: a group of oncology physi-
cians working in a clinic at a public hospital and two
groups of molecular biologists conducting basic research,
one employed at a public university and the other in a pri-
vate biopharmaceutical company. The reason for selecting
these three groups of respondents is to explore whether
ethical problems about human beings are perceived as
more distant for molecular biologists than for physicians
due to the fact that physicians work with human beings in
a doctor-patient relationship, whereas molecular biolo-
gists investigate human material such as DNA and cells in
cultures. Another consideration might be the location of
employment for molecular biologists, e.g. at a public uni-
versity or in a private biopharmaceutical company. This
difference in location of employment could influence the
motive for ethical evaluation of research. Hypothetically,
the motive for the ethical evaluation of the research of
molecular biologists employed at a public university
could be an interest in ethically good behaviour, in con-
trast to perhaps an overall economic motive for molecular
biologists employed in a private biopharmaceutical com-
pany.
The findings of this larger project, however, are so com-
prehensive that they are being presented in several arti-
cles. The findings presented in other articles are
summarised here.
We found similarities in the character of the daily work of
molecular biologists employed in a private biopharma-
ceutical company and oncology physicians working in a
clinic at a public hospital. With regard to research goals
and driving force, both of these groups have a specific
effort of beneficence in mind. Their motivation is to help
sick people. Molecular biologists employed in a private
biopharmaceutical company conduct basic research with
the aim of developing pharmaceuticals. Oncology physi-
cians treat patients suffering from serious cancer and per-
form clinical trials with the aim of developing cancer
therapies. In contrast, molecular biologists employed at a
public university do not have any specific effort of benef-
icence in mind in their daily work; their research goal is to
provide answers to basic research questions.
With regard to funding and efficiency, we see similarities
between the two groups of respondents employed by pub-
lic institutions. Molecular biologists employed at a public
university and oncology physicians employed at a public
hospital think that a lot of time is spent on paperwork and
that resources are limited. Both of these groups are under
stress, either because they are applying for funding for
basic research or because they are treating as many
patients as possible per day in the out-patients' clinic. In
contrast, molecular biologists employed in a private biop-
harmaceutical company have time allocated to read scien-
tific articles and experience being able to decide the
amount of work they will do themselves.
Oncology physicians working in a clinic at a public hospi-
tal perceive ethical evaluation as part of their daily work.
They discuss in groups how to treat patients, and they
have interdisciplinary seminars. This might be due to the
fact that they work with human beings in a doctor-patient
relationship in contrast to conducting basic research. On
the other hand, molecular biologists employed at the uni-
versity conducting basic research with the aim of answer-
ing basic research questions do not talk about ethics in
their daily work and they do not want to prioritise partic-Philosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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ipation in seminars on ethics because they have a busy
schedule. This contrasts with the group of molecular biol-
ogists employed in a private biopharmaceutical company.
The private company prioritises ethical evaluation
because of the investors. If the company behaves unethi-
cally, they will be punished by the consumers and by the
investors in the long run.
Background
Researchers have particularly focused on formulating eth-
ical principles that reflect the ethical issues at stake in bio-
medicine and on analysing what principles should be
used to evaluate ethical problems in the field. After exam-
ining considered moral judgements in biomedicine, two
American bioethicists, Tom L. Beauchamp & James F.
Childress [16], became convinced that the principles of
respect for autonomy, nonmaleficence, beneficence and
justice are central to and play a vital role in biomedicine.
In table 1, we present a brief formulation of the bioethical
principles of Beauchamp & Childress.
According to Beauchamp & Childress, no one principle
ranks higher than the others. Which principles should be
given most weight depends on the context of the given sit-
uation. Beauchamp & Childress consider the four princi-
ples as prima facie binding, i.e. they must be fulfilled,
unless they conflict on a particular occasion with an equal
or stronger principle. This type of principle is always bind-
ing unless a competing moral obligation overrides or out-
weighs it in a particular circumstance. Beauchamp &
Childress write: "Some acts are at once prima facie wrong
and prima facie right, because two or more norms conflict
in the circumstances. Agents must then determine what
they ought to do by finding an actual or overriding (in
contrast to prima facie) obligation" [16]. This means the
agents must locate the best balance of right and wrong by
determining their actual obligations in such situations by
examining the respective weights of the competing prima
facie obligations (the relative weights of all competing
prima facie norms). In the latest edition of their book,
Principles of Biomedical Ethics, Beauchamp & Childress
specify conditions that should be fulfilled for one prima
facie principle to weigh heavier than another. They also
describe how to specify the principles [16]. According to
Beauchamp & Childress, there is no straightforward
movement from principles to particular judgments. Prin-
ciples are only starting points and, as such, general guide-
lines for the development of norms of appropriate
conduct. Principles need to be supplemented by paradigm
cases of right action, empirical data, organisational expe-
rience, etc. Rights, virtues and emotional responses are as
important as principles for ethical judgement [16].
Beauchamp & Childress believe that the principles of their
theory find support across different cultures. They claim
that the principles are part of a cross-cultural common
morality and that in all cultures people who are serious
about moral conduct accept the norms of this common
morality [16]. However, even though these principles are
generally acknowledged, this does not mean that there is
consensus about what is good and bad. Interesting
debates occur when the principles are to be interpreted,
specified and balanced in specific historical, social, eco-
nomic and political contexts.
Although Beauchamp & Childress' theory is one of the
most influential bioethical theories, it is, of course, also
subject to much philosophical discussion [18-31]. Much
of the criticism focuses on the application of principles,
i.e. the problems of balancing and specification. However,
some criticism is also focused on the choice of principles
and their content. There is no doubt that Beauchamp &
Childress were much inspired by W. D. Ross [32], who
claims in The Right and the Good (1930) that common
sense tells that we have some prima facie duties (also
called conditional duties) to do special acts (e.g. keeping
a promise). Ross [32] regards the duties of fidelity, repara-
tion, gratitude, justice, beneficence, self-improvement
and nonmaleficence as prima facie duties. In line with
Ross, Beauchamp & Childress regard the four bioethical
principles as prima facie binding and their choice of prin-
ciples is almost in agreement with Ross' prima facie
duties.
Table 1: The Four Principles of Biomedical Ethics.  A brief 
formulation of the four bioethical principles of respect for 
autonomy, beneficence, nonmaleficence and justice of 
Beauchamp & Childress [16].
The Principle of Respect for Autonomy
• As a negative obligation: Autonomous actions should not be 
subjected to controlling constraints by others
• As a positive obligation: This principle requires respectful treatment 
in disclosing information, probing for and ensuring understanding and 
voluntariness, and fostering autonomous decision-making [16].
The Principle of Beneficence
• One ought to prevent and remove evil or harm
• One ought to do and promote good
• One ought to weigh and balance the possible goods against the 
possible harms of an action [16, 17].
The Principle of Nonmaleficence
One ought not to inflict evil or harm. Or more specifically: One ought 
not to hurt other people mentally or physically [16].
The Principle of Justice
Beauchamp hildress examine several philosophical theories of justice, 
including egalitarian theories which emphasise "equal access to the 
goods in life that every rational person values (often invoking material 
criteria of need and equality)" [16]. Beauchamp & Childress propose 
that "society recognize an enforceable right to a decent minimum of 
health care within a framework for allocation that incorporates both 
utilitarian and egalitarian standards" [16]. (Utilitarian theories 
emphasise "a mixture of criteria for the purpose of maximizing public 
utility") [16].Philosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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There is a lot of controversy about what principles reflect
the ethical considerations at stake in biomedicine and, as
a result, which principles should be used to analyse ethi-
cal problems in the field. Beauchamp [31] claims that the
efficacy of the four principles can be tested empirically
and that it can be determined whether they are part of a
cross-cultural common morality. He does not present any
empirical data generated systematically by qualitative
research methods to support this position. However, he
does invite the design of an empirical research project to
investigate the question. What is needed is to construct an
empirical study to investigate ethical reasoning in bio-
medicine. This was the overall purpose of the larger
research project, 'Bioethics in Theory and Practice'.
Aim
Our aim was to test empirically whether there is a differ-
ence in the ethical considerations or principles at stake
between Danish physicians and Danish molecular biolo-
gists.
Research questions:
￿ Is there a difference in the ethical considerations or prin-
ciples at stake between physicians and molecular biolo-
gists?
￿ Is there a difference in the ethical considerations or prin-
ciples at stake between molecular biologists employed at
a public university and molecular biologists employed in
a private biopharmaceutical company?
Study design and methods
The basic approach of the project was phenomenological
hermeneutical. This approach was used both in the design
of the interview guide and in the interpretation of data.
However, to make the approach normative, the phenom-
enological hermeneutical method was combined with
WRE as a decision procedure in the construction of the
interview guide, as described in Ebbesen & Pedersen [7].
The sample
This study is based on 12 interviews with physicians and
molecular biologists (table 2). The type of sampling used
was random purposeful (random selection to select lim-
ited numbers of cases from a larger purposeful sample).
The sample size was determined in relation to data satura-
tion. The decisive criterion for sample size is the point
where variation ceases; saturation tends to occur when the
number of interviews reaches around 15 ± 10 [33,34]. We
observed that data saturation was beginning to appear
after interviewing nine respondents (three respondents in
each group). The inclusion criteria for this study were that
the participants should have an academic degree in medi-
cal science or molecular biology and more than five years'
working experience, so they have a thorough and pro-
found knowledge of practice. Excluded from the study
were people who did not meet the inclusion criteria, did
not speak Danish, or had not been brought up in Den-
mark.
Interview guide
The ethical reasoning of physicians and molecular biolo-
gists was explored by use of semi-structured interviews
[34]. The interview guide used consists of 13 main ques-
tions (table 3), each containing a number of sub-ques-
tions (the sub-questions are not shown in the table). Each
interview lasted for 1 hour and 5 minutes on average, and
the interview was transcribed word-for-word in text form.
There is a detailed description of the theory behind the
interview questions in Ebbesen & Pedersen [7].
Data analysis
The data were analysed using a phenomenological herme-
neutical method for interpreting interview texts inspired
by the theory of interpretation presented by Ricoeur as
cited in Lindseth & Norberg [3] and Pedersen [35]. In the
following, the three steps of data analysis are briefly
described.
Naïve reading
The text is read several times in order to grasp its meaning
as a whole. The interpreter tries to read the text with a phe-
nomenological attitude, so as to be open enough to allow
the text to speak to him/her. The naïve reading is regarded
as a first conjecture and it has to be validated or invali-
dated by the subsequent structural analysis [3].
Table 2: Sample description
Respondents 
(number)
Respondent 
group
Age 
(years)
Males 
(number)
Females 
(number)
4 Oncology 
physicians working 
in a clinic at a 
public hospital
45–59 3 1
4M o l e c u l a r  
biologists 
employed at a 
public university 
working in a 
laboratory 
conducting basic 
research
31–57 2 2
4M o l e c u l a r  
biologists 
employed in a 
private 
biopharmaceutical 
company working 
in a laboratory 
conducting basic 
research
36–57 1 3Philosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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Structural analysis
According to Ricoeur, to understand a text is to follow its
movement from what it says to what it talks about [3,35].
In the structural analysis, we move from what the text says
to what it talks about, first describing units of meaning
(what is said) and then identifying and formulating units
of significance (what is talked about) and themes (table 4)
[35].
First, the whole text is read and divided into units of
meaning (what is said). These units of meaning can be
part of a sentence, a sentence or a paragraph. Secondly,
the units of meaning are reflected on in relation to the
naïve understanding. Then the units of meaning are
sorted and condensed and units of significance are formu-
lated (what is talked about). Next, units of significance are
condensed even more and themes are formulated. A
theme is a thread of meaning that continues in several
parts of the text. A theme identifies an essential meaning
of lived experience; these themes are formulated as con-
densed descriptions and abstract concepts [3,35].
During the structural analysis, the text is viewed as objec-
tively as possible by decontextualising the units of mean-
ing from the text as a whole, so that the text parts are
considered as independently as possible from their con-
text in the text [3,35].
The themes are reflected on against the background of the
naïve understanding to see whether the themes validate or
invalidate the naïve understanding. If the structural anal-
ysis invalidates the naïve understanding, the whole text is
read again and a new naïve understanding is formulated
and checked by a new structural analysis. This process of
comparing the naïve reading and the structural analysis is
repeated until the naïve understanding is validated
through the structural analysis [3,35].
Critical interpretation
The themes are reflected on in relation to the literature.
The text is read again as a whole with the naïve under-
standing and the validated themes in mind and as open-
mindedly as possible. However, according to Lindseth &
Norberg [3], we interpret in relation to our pre-under-
standing and we cannot free ourselves from this pre-
understanding. This is in line with Gadamer, who thinks
that the hermeneutic mode of interpreting meaning is not
without presuppositions, like the phenomenological
description. The interpreter of a text cannot 'jump outside'
the tradition of understanding he or she lives in [36,37].
The interpreter should, however, attempt to make such
presuppositions or foreknowledge explicit [36]. Fore-
knowledge in this project includes the literature stated in
the 'Reference' section in this article. According to Lind-
seth & Norberg [3], one can find literature that may be
appropriate for helping to revise, widen and deepen our
Table 3: Interview guide
The interview guide below was used in the present study of the ethical reasoning of physicians and molecular biologists. It consists of 13 main 
questions, each containing a number of sub-questions (the sub-questions are not presented here).
1. Please describe your background
2. Please describe your working day
3. What are the positive/satisfactory aspects of your job?
4. What are the negative/unsatisfactory aspects of your work?
5. In your profession, what makes a person qualified?
6. What are the perspectives of your research?
7. Have you ever been faced with difficult decisions about whether or not to participate in a research project? Or how to treat a patient?
8. Do you feel well-prepared to assess ethical problems about your participation in a research project? Or about what kind of treatment a patient 
should receive?
9. Presentation of an actual case:
In 2003, it was reported in Science that 2 out of 10 patients treated with retroviral mediated gene therapy against the immune system disease SCID-
X1 developed leukaemia three years after the treatment. The gene therapy resulted in a functional immune system in 9 out of 10 patients, but 2 
patients developed T cell leukaemia caused by insertional mutagenesis. What is your immediate assessment of this case?
10. Presentation of an actual case:
In 2002, the Danish newspaper Information reported how an Italian obstetrician had fertilized an infertile woman using the clone of a man. What is 
your immediate assessment of this case?
11. Presentation of bioethical principles:
Some bioethicists argue that four ethical principles have to be balanced when it comes to assessing bioethical cases: Respect for the patient's 
autonomy, an obligation to do good (beneficence), an obligation not to harm (nonmaleficence) and just and equal distribution of welfare services. 
How do you understand these concepts? Are these principles at stake in your practice?
Other bioethicists believe that the principle of respecting the patient's autonomy is too narrow to protect the human person, and that it should be 
supplemented with the principles of respect for the patient's dignity, vulnerability and integrity. How do you understand these concepts? Are these 
principles at stake in your practice?
12. Is the amount of time/resources available to you in your daily work sufficient to reflect on ethical issues?
13. Have you been involved in the implementation of concrete initiatives, projects or seminars about ethical issues in your profession?
Main questions in the interview guide used in the present study.Philosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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understanding of the text. This is where existing bioethical
theory for data interpretation comes in. It can be used to
structure the comprehensive understanding of the text,
present alternative views and maybe revise the structure
already made. However, since this was a phenomenologi-
cal hermeneutical study, we did not force the literature
perspective on the interview text, but let the literature illu-
minate the interview text and the interview text illuminate
the literature [3,35].
Results
From the structural analysis, a number of themes
emerged, and these themes are explored in details below.
The health of the patient in focus
Molecular biologists employed in a private biopharma-
ceutical company have the patient in focus when they
plan research projects. They describe their research aims as
gaining knowledge about cell, protein and gene functions
Table 4: Example of structural analysis – the movement from what is said to what is talked about, first by describing units of meaning 
(what is said) and next by formulating units of significance (what is talked about) and themes.
Respondent group Units of meaning (What is said) Units of significance 
(What is talked about)
Themes
Oncology physician 
working in a hospital 
clinic (OPC, Q1)
... you meet a large number of extremely wonderful and 
brave people who by ill luck end up here due to serious 
illness ... most people deal with their fate extremely well ... 
they mobilise resources that people are not usually 
expected to possess. But most of them do ... It is an 
immense satisfaction for me ... when I have one of those 
tough outpatient departments, and I have seen 20 or 25 
patients, and I can see that many of them have responded 
well to treatment, have recovered, are able to function 
and are happy and satisfied ... The patient's recovery is 
often preceded by a hard period of therapy during which 
he or she suffers a lot of pain and discomfort due to 
radiation therapy or an operation. And then the patient 
recovers. It is an immense satisfaction for me to witness 
that – there is nothing better, is there?
Satisfaction by helping 
many brave people who 
mobilise reserves of 
energy to get through 
serious treatment
Beneficence
Molecular biologist 
employed in private 
biopharmaceutical 
company (MBP, Q2)
It is a part of clinical development – to prove that it is safe 
... not just for mice, but various animal models – it 
depends on the type of protein ... you have to prove that it 
does not produce cardiac problems or cancer ...
Clinical trials to show 
that biopharmaceuticals 
are not potentially 
dangerous Animal 
models Cardiac problems 
Cancer
Nonmaleficence
Molecular biologist 
employed at the 
university (MBU, Q3)
You must inform them of their options and then respect 
their decision.
Inform patients and 
respect their decision
Respect for autonomy/
Informed consent
• Respect decision
• External constraints
Oncology physician 
working in a hospital 
clinic (OPC, Q4)
... try to determine what is wrong with the patient, what 
are our options, what are the patient's wishes, ideas, and 
then we have to reach some kind of mutual understanding, 
a frame of reference, and take it from there ... and how we 
can deal with this in respect of that.
Medical prognosis Risk-
benefit analysis Patient's 
wishes and ideas Mutual 
understanding Respect
Medical prognosis
• Risk-benefit analysis
Respect for autonomy/
Informed consent
• Patient's wishes and 
ideas
• Mutual understanding
• Respect
Molecular biologist 
employed in private 
biopharmaceutical 
company (MBP, Q5)
... from a general perspective, we need a good reason for 
doing all the things we do. We are a PLC, so the biggest 
reason for us is the fact that we have to earn money for 
our shareholders, but we also need take into 
consideration the benefit of society, not just our own 
good, because all things are connected. If we start doing 
something unethical, then it will damage us in the long run 
...
Important for company 
to have ethical profile, 
since it pays off
Justice
Oncology physician 
working in a hospital 
clinic (OPC, Q6)
Resources are scarce and the number of patients in need 
of radiotherapy is increasing ... you have so many patients 
and you want to be able to cure as many as possible from 
their cancer, which is, after all, the main problem. But 
what is the best way to do it so that the patients become 
most well-functioning afterwards, cosmetically and 
functionally?
More patients than 
devices, how to manage 
resources most 
effectively
Justice
• Just distributionPhilosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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in order to develop biopharmaceuticals to help patients.
This means they have a specific effort of beneficence in
mind. This is seen in MBP, Q7, below.
MBP, Q7:
... We are employed here to produce drugs for the benefit of
the patients, so we have to see things in a broader perspec-
tive ... of course, that is not where your focus is when you
are about to clone something and considering what restric-
tion sites to apply. At that moment, the overall perspective
is not the focus of your attention, but you have to keep it in
the back of your mind as part of your daily activities in order
for things to make sense in the end.
But although the individual researcher in the biopharma-
ceutical company has the beneficence of the patient in
focus when planning new projects, the choice of the man-
agement of the company to start up a new project has to
do with economics. This is seen in MBP, Q8, below.
MBP, Q8:
It requires a willingness to accept that you are not always able
to finish your job completely, because sometimes you reach a
conclusion where you have to admit that this part was not so
good anyway – we may lack some answers, but we never get
around to ... we cannot defend the continuation of the work,
and therefore we close this activity now. You need to accept that
you cannot complete all your work in detail, but the positive side
is the fact that there are always exciting new projects to address
and take further ... but, of course, you always have to weigh the
financial aspects ... There needs to be an indication that this
could potentially become a drug before it is even recognised as
a project.
In contrast to molecular biologists employed in a pri-
vate biotechnology company, molecular biologists
employed at a public university do not have any spe-
cific effort of beneficence in mind; their research goal
is to provide answers to interesting basic research
questions so as to accumulate knowledge. They
describe their research aims as gaining knowledge
about fundamental cell, protein and gene functions.
This is seen in MBU, Q9, below.
MBU, Q9:
... our overall goal is to understand how interferon works ...
it is pure basic research.
Oncology physicians working in a clinic at a public hospi-
tal describe their research aims in a similar way to molec-
ular biologists employed in a private biopharmaceutical
company; they have a specific effort of beneficence in
mind. Oncology physicians regard the goal of clinical tri-
als as developing better treatment for patients. Their moti-
vation is to help sick people. This is seen in quotation
OPC, Q1, table 4. When deciding the inclusion criteria for
a clinical trial, physicians firstly have the present patient
in focus and consider how this experiment can benefit this
patient. Secondly, the physician considers how this exper-
iment can benefit future patients. This is seen in OPC,
Q10, below.
OPC, Q10:
We have to give consideration to the patients first and fore-
most. If you are about to make an experiment, considera-
tion for the patient comes first, but there are also all the
future patients to consider. You have to constantly try to
gain more insight, and perhaps you can kill two birds with
one stone by offering a patient the chance to participate in
an experiment.
Oncology physicians find that patients suffering from ter-
minal illnesses want to participate in trials to benefit other
patients. This is seen in OPC, Q11, below.
OPC, Q11:
The more ill you are, and the more hopeless your own situ-
ation is, the more ... So you try to attach some meaning to
your situation, so that it can at least be to some use for oth-
ers. Then I think you make a ... You try to find some sense
in it and some ... Something positive is bound to come out
of all this misery. If nothing else, greater knowledge on a
collective basis.
Risks and dangers
Molecular biologists employed in a private biopharma-
ceutical company or at a public university face minimal
environmental and health risks regarding radioactivity
and chemicals when conducting basic research. This is
seen in quotation MBU, Q12, below. With regard to
experiments in cell cultures, they believe that mammalian
cells have a built-in safety margin against spreading to
nature, since cells are sensitive and need to be treated well
if they are not to die. Furthermore, molecular biologists
experience very strict safety guidelines. This is seen in quo-
tation MBP, Q13, below.
MBU, Q12:
It is minimal, but we do work with radioactivity, so that is
one risk factor. But we use very small amounts ... a few
chemicals that you should not eat directly ...
MBP, Q13:Philosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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The cells we use ... mammalian cells are generally very sen-
sitive. If you do not treat them really, really well, they die
... So this is a margin of safety in itself ... I mean, against
spreading to nature for instance ... and we also have sys-
tems to kill them before anything spreads to nature. As a
precaution, we have very strict rules against pouring it
down the sink. Everything needs to be ... sterilised. Every-
thing is either autoclaved or we ... add something to the cell
media and cell cultures that we use to kill the cells.
Molecular biologists employed in a private biopharma-
ceutical company carry out animal testing to investigate
whether biopharmaceuticals may produce cardiac prob-
lems or cancer. This is seen in MBP, Q2, table 4 and in
MBP, Q14, below.
MBP, Q14:
Clinical development is about finding out if whether or not
this is an effective and safe treatment ... if it is not safe,
then it is no use ... You cannot accept a treatment that
makes people ill.
Molecular biologists employed at the university stress that
toxicology tests are always performed in animal models
and not in humans the first time. This is seen in MBU,
Q15, below:
MBU, Q15:
Toxicology tests, for instance. You do not perform them on
humans the first time. You always use some kind of test ani-
mal the first time.
To develop the most efficient cancer therapies with the
fewest side effects, oncology physicians carry out clinical
trials. They always consider how toxic the treatment is.
When physicians decide whether or not to ask a patient to
participate in a trial, the physician takes the situation of
the patient into account. They consider whether the
patient is suffering from a serious disease, whether the dis-
ease is curable or whether palliative care is needed. This is
seen in quotations OPC, Q16–17, below.
OPC, Q16:
... how to offer a cancer treatment that would be both effec-
tive and cause as few side-effects as possible. That is the bal-
ance we need to strike. The balance between our effective
remedies – that include surgery, radiation and chemother-
apy – and the whole person who has be able to function
afterwards.
OPC, Q17:
And of course, it must be viewed in the light of the serious-
ness of the situation. Are we dealing with potentially
healthy patients or terminal ones? ... But in both cases you
have to consider – even in the case of terminal patients: is
it a real possibility? – and what kind of cost considerations
are involved if they participate – how toxic is this?
According to molecular biologists employed at the univer-
sity, ethical boards have to evaluate potential experiments
or clinical trials in order to minimise the harm done to
human subjects and patients. This is seen in quotation
MBU, Q18, below:
MBU, Q18:
But somebody has to check that the professional skills and
expertise are satisfactory before you ...otherwise, some
smart Alec who makes an unconsidered choice ...
Informed consent, external constraints, vulnerability and 
role reversal
In the study, we see examples of how molecular biologists
find that informed consent can be influenced by external
constraints. For instance, in MBU, Q3, table 4, a molecu-
lar biologist employed at the university says that patients
must be informed of their options regarding treatment or
trials and that their decision regarding these issues should
be respected. This quotation indicates that informed con-
sent should be respected without external constraints.
However, in MBP, Q19, below, a molecular biologist
employed in a private biopharmaceutical company
stresses that very ill patients will accept any treatment,
they will accept the risks involved, they are vulnerable and
constrained by the circumstances to make a certain choice.
MBU, Q20, presented below, illuminates the same issues
and says that patients and human subjects should decide
themselves, but that very ill patients are constrained by
the circumstances to make a certain choice.
MBP, Q19:
... if you were a seriously ill or terminally ill patient, I think
I would accept just about any treatment, because you would
accept the risk involved.
MBU, Q20:
... people make their own choices; if you inform people of
the risks, they must make the decision themselves. The prob-
lem is if they feel they are forced into it. Some may feel this
way; it depends on the person.
Molecular biologists employed in a private biopharma-
ceutical company or at the university believe that if they
were patients suffering from serious cancer, they wouldPhilosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
Page 10 of 16
(page number not for citation purposes)
accept any treatment independent of side effects. They
imagine themselves being in the situation of the patient
(role reversal). This is seen in quotation MBU, Q21 and
MBP, Q22, below.
MBU, Q21:
... often you try to put yourself in that person's shoes; if it
was your child or if you were the patient, would you run
that risk ...
MBP, Q22:
...if you tell a cancer patient: Do you want this treatment?
– it will prolong your life by three months on average. If you
were in that situation yourself, you would say: yes, give me
this treatment. You could decide to live with various side-
effects ...
Respect for autonomy based on the patient's wishes and 
ideas, information and understanding
Oncology physicians believe that informed consent or
refusal is based on the patient's wishes and ideas, infor-
mation and understanding. For instance OPC, Q4, table
4, says that in dialogue with the patient, the physician per-
forms a medical prognosis or risk-benefit analysis based
on the patient's wishes and ideas, mutual understanding
and respect. Furthermore, OPC, Q23, below, stresses that
the physician has a positive obligation to adjust to the
level of the patient when disclosing information to make
sure that the patient understands. OPC, Q24, below,
emphasises that the tasks of the physician are 1) to dis-
close information so that the patient can make informed
consent, and 2) to respect this informed consent.
OPC, Q23:
... patients are very different and you must adjust to their
level as best you can and try to work out what kind of lan-
guage to speak and sense whether they have understood
what you have told them, and maybe repeat it...
OPC, Q24:
My task is to ensure as well as possible that they know ...
receive information on what we can offer and what options
are available to them in their situation. And that the infor-
mation is communicated in such a way that it forms the
basis of their decision-making. If they then decide some-
thing else, then that is that.
The principle of respect for autonomy does not apply
Oncology physicians think that there are situations, where
the principle of respect for autonomy does not apply.
OPC, Q25, below, describes such a situation.
OPC, Q25:
... when we have a protocol like that – there is the inclusion
criteria ... the patient may meet all the criteria, but when I
sit in front of the patient, I think to myself: this just will not
work. This patient is in some sort of crisis or situation in
which it is not fair to ask them to make this kind of deci-
sion. And then I can choose to say to myself that it is not
fair. Then we give them the standard treatment ... once in
a while I decide that they are not capable of making these
decisions themselves. It is not fair to place the strain and
stress of having to make such a decision on them – because
it is a strain.
OPC, Q25 stresses that the physician's decision about
treatment depends on the physical and psychological con-
dition of the patient. Furthermore, the quotation tells us
that the physician avoids asking the patient to make a
decision if the patient is in a difficult situation, since it is
not fair or just under these circumstances to place stress on
the patient.
Clinical trials in developing countries, fairness, limited 
resources, public funding and waiting lists
Molecular biologists employed in a private biopharma-
ceutical company have interdisciplinary working groups
that discuss the ethical and legal issues of the use of
human material and animal models. One reason the com-
pany prioritises ethical evaluation is because of the inves-
tors: if the company behaves unethically, they will be
punished by the consumers and by the investors in the
long run. This means it is important for the company to
have an ethical profile, since it pays off. This is seen in
MBP, Q5, table 4. The private biopharmaceutical com-
pany performs clinical trials in developing countries. To
benefit the research subjects, they are assigned a lifetime
of treatment. The company's motive in helping develop-
ing countries has to do with economics. This is seen in
MBP, Q26, below.
MBP, Q26:
Generic drugs and placing drugs at the disposal of countries
that cannot afford them. These are issues that management
deals with, and there are guidelines ... on how to behave, if
you make clinical experiments in a country that would not
normally offer this kind of treatment. Then you should –
well, not just should, but must – offer life-long treatment to
the individuals involved, if it turns out that this clinical test
is related to an effective treatment ... we have departments
that are responsible for clinical experiments, and these are
the kinds of things they deal with: Where can you carry out
your clinical experiments, in which countries? And a
number of things may speak in favour of the richest coun-
tries because then you will not be accused of ... exploitation.Philosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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But there can also be good reasons for choosing less rich
countries, because it gives them the opportunity to be
included in treatment. And XX does it to some degree ...
there are clinics established by XX in Africa, India and ...
that are simply ... at XX's expense, and – you may say –
compared to marketing budgets it is not a whole lot of
money ... obviously, if you realise that it pays off. But at the
same time it is a good thing.
Oncology physicians working in a clinic at a public hospi-
tal are dissatisfied with the management demands for effi-
ciency. They think that budgets and demands for
efficiency do not fit together and that the waiting lists are
too long. The oncology physicians believe that they have
to treat too many patients per day in the out-patients'
clinic, since there is a limit to how many patients they can
treat per day with empathy. This is seen in quotations
OPC Q27–Q29, below.
OPC, Q27:
It is a demand from the management who ... it has been
decided ... Budgets are decided and followed by demands
and expectations of a specific number of patients to be
attended to within the framework of the budget, and these
ends do not meet. We quite often have waiting lists, and
that is very unsatisfactory ...
OPC, Q28:
... You know there are already ten people in the waiting
room and if you fall behind schedule, they will push you and
ask you if it is not their turn? They are also nervous, because
they are going to be tested. So it is all a race against time.
OPC, Q29:
... it is dissatisfactory if the outpatient department pro-
gramme is too tight ... if the production demand is too
great. There is a limit to how many patients you can contain
in your head in one day; to how much negative news you
can give patients without becoming a tape recorder ... sort
of a factory where things are weighed and measured that
way.
Oncology physicians find that resources are limited, they
have too few instruments and too little equipment com-
pared to the number of patients suffering from cancer,
and they want to treat as many patients as possible in the
best way. This is seen in OPC, Q6, table 4. However, the
physician does not consider that resources are limited
when deciding treatment for the individual patient. This is
seen in OPC, Q30, below.
OPC, Q30:
I do not take into consideration that it will cost us 100.000
if we have to use Tascol again. I have not taken into consid-
eration that it is too expensive. Not in relation to the indi-
vidual patient, but of course, when we hold a meeting and
the administrator informs us of the size of the current drugs
budget, and that the expected payments deficit will be such
and such if we initiate the new treatment, and we do not
have the capacity or the staff to do it, and we do not have
the means – or whatever – then you think about the finan-
cial aspects. But when you are facing the individual patient,
you do not think too much about it.
Molecular biologists employed at a public university also
find that resources are limited. They are stressed since they
are under a constant pressure to apply for funding for
research and the competition is hard. This is seen in MBU,
Q31, below.
MBU, Q31:
...difficult to raise enough money to make ends meet. You
are quite isolated, doing your own thing and raising money
for it ... so basically we are competing for the same money
...publication is a prerequisite for being able to raise funds
– so that is where the shoe pinches: to get your work
financed to be able to continue...and if you need material
for your test tubes, or equipment or the like, you have to find
a way of getting it ... that is what puts me under the most
stress, I would say ... excellent researchers do not work alone
...
Discussion
In what follows, the findings of the structural analysis are
interpreted and discussed in relation to the literature.
Beneficence and nonmaleficence considerations
When interpreting the interview texts, we see similarities
in the research aims of the group of molecular biologists
employed in a private biopharmaceutical company and
those of the oncology physicians working in a clinic. Both
of these groups have the health of the patient in focus in
their daily work. Oncology physicians regard the goal of
clinical trials as developing better treatments with fewest
side effects. Furthermore, oncology physicians find that
patients suffering from terminal illnesses want to partici-
pate in trials to benefit other patients. Molecular biolo-
gists employed in a private biopharmaceutical company
also have the patient in focus when they are planning
research projects. They describe their research aims as
gaining knowledge about cell, protein and gene functions
in order to develop biopharmaceuticals to help patients.
This means that the motivation of these groups is to help
sick people by developing better treatment with fewer side
effects. This reflects all three parts of the principle of
beneficence of Beauchamp & Childress: 1) One ought toPhilosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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prevent and remove evil or harm, 2) One ought to do and
promote good and 3) One ought to weigh and balance the
possible goods against the possible harms of an action
[16,17]. In contrast, molecular biologists employed at a
public university do not have any specific effort of benef-
icence in mind; their research goal is to accumulate
knowledge by providing answers to interesting basic
research questions. They describe their research aims as
gaining knowledge about fundamental cell, protein and
gene functions.
The kinds of nonmaleficence considerations taken into
account by the three groups of respondents differ signifi-
cantly. The nonmaleficence considerations of molecular
biologists employed at the university or in a private biop-
harmaceutical company are related to the environment, to
the researchers' own health, to animal models, and only
implicitly to human subjects. Molecular biologists face
environmental and health risks with regard to radioactiv-
ity and chemicals, but they consider these as minimal.
Furthermore, molecular biologists believe that the mam-
malian cells they use for experiments have a built-in safety
margin against spreading to nature, since the cells are sen-
sitive and need to be treated well if they are not to die.
Molecular biologists employed in a private biopharma-
ceutical company perform tests on animal models to
investigate whether biopharmaceuticals produce cardiac
problems or cancer. Molecular biologists employed at the
university state that such toxicology tests are always per-
formed on animal models and not in humans the first
time. They stress that the reason why ethical boards have
to evaluate potential experiments or clinical trials is to
minimise the harm done to research subjects and patients.
From this we see, that the moral principle governing the
treatment or non-treatment of patients is nonmaleficence.
The obligation not to inflict harm is an obligation that co-
travels with an obligation to test the drug in animal mod-
els before delivering the drug to human subjects or
patients. This is also the reason ethical boards have to
evaluate potential experiments or clinical trials. We have
established procedures intended to minimise the harm
done to patients and that reflect the principle of nonma-
leficence and the first part of the principle of beneficence
of Beauchamp & Childress.
The nonmaleficence considerations of oncology physi-
cians have to do with patients or human subjects. Oncol-
ogy physicians say that they perform clinical trials in order
to develop the most efficient cancer therapies with the
fewest side effects. For instance, they take into account
how toxic chemotherapy is. When physicians decide
whether or not to ask a patient to participate in a trial, the
physician takes the situation of the patient into consider-
ation: Does the patient suffer from a serious disease? Is the
disease curable? Or does the patient need palliative care?
As we see, physicians want to provide the maximum ben-
efit but at the same time physicians do not want to intro-
duce harm. Physicians consider the negative side effects of
radiation and chemotherapy. They make judgements in
each case as to whether or not the drug chosen is actually
going to cause harm rather than hold out a substantial
promise of benefit. The physician is concerned not only to
benefit the patient but also not to harm the patient, which
means that there is a beneficence consideration, a nonma-
leficence consideration, and the balance between them.
This reflects the principle of nonmaleficence and the three
parts of the principle of beneficence of Beauchamp &
Childress.
According to Beauchamp & Childress the evaluation of
risk in relation to probable benefit is often labelled risk-
benefit analysis. They say that the term risk refers to a pos-
sible future harm, where harm is defined as a setback to
interests, particularly in life, health and welfare [16].
Statements of risk are both descriptive and evaluative.
They are descriptive inasmuch as they state the probability
that harmful events will occur, and they are evaluative
inasmuch as they attach a value to the occurrence or pre-
vention of these events [16]. Commonly in the field of
biomedicine, the term benefit refers to something of posi-
tive value, such as life or health. The risk-benefit relation-
ship may be conceived in terms of the ratio between the
probability and magnitude of an anticipated benefit and
the probability and magnitude of an anticipated harm.
Use of the terms risk and benefit necessarily involves an
evaluation. Values determine both what count as harms
and benefits and how much weight particular harms and
benefits have in the risk-benefit calculation [16]. The
terms harm and benefit, defined as stated above, are ethi-
cally relevant concepts. Ethical obligations or principles
about not inflicting harm (nonmaleficence) and promot-
ing good (beneficence) are generally accepted [16].
According to Beauchamp & Childress, the balancing of the
general ethical principles of nonmaleficence and benefi-
cence is not symmetrical, since our obligation not to
inflict evil or harm (nonmaleficence) is more stringent
than our obligation to prevent and remove evil and harm
or to do and promote good (beneficence) [16]. This was
also shown in the present study, in all three groups of
respondents: that the moral principle governing the treat-
ment or non-treatment of patients (or participation in
research) is nonmaleficence.
Respect for autonomy as a negative obligation – informed 
consent, role reversal and vulnerability
In this study, we have seen how the two groups of molec-
ular biologists employed in private biopharmaceutical
company and at the university state that the informed
consent of human subjects or patients can be influenced
by external constraint. Molecular biologists say thatPhilosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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patients must be informed of their options regarding
treatment or trials and that their decision regarding these
issues should be respected. This indicates that informed
consent should be respected without external constraints.
At the same time molecular biologists stress that very sick
patients would accept any treatment, they would accept
the risks involved, since they are vulnerable and con-
strained by the circumstances to make a certain choice.
Following Beauchamp & Childress, this reflects the princi-
ple of respect for autonomy as a negative obligation which
says that autonomous actions should not be subjected to
controlling constraints by others [16].
Respect for autonomy as a positive obligation – 
information, understanding and the patient's wishes and 
ideas
Like molecular biologists, oncology physicians experience
the principle of respect for autonomy as a negative obliga-
tion, since they see informed consent of the patient as an
obligation that should be respected without external con-
straint, i.e. the physician must respect the decision of the
patient even when it is not the one he/she has recom-
mended.
However, in contrast to molecular biologists, oncology
physicians also experience the principle of respect for
autonomy as a positive obligation. The principle of
respect for autonomy as a positive obligation requires
respectful treatment in disclosing information, probing
for and ensuring understanding and voluntariness, and
fostering autonomous decision-making [16]. This is seen
in the way oncology physicians believe that they have a
positive obligation to adjust to the level of the patient
when providing this information to make sure that the
patient understands. Furthermore, in dialogue with the
patient, they perform a medical prognosis or risk-benefit
analysis based on the patient's wishes and ideas, with
mutual understanding and respect.
The principle of respect for autonomy does not apply – the 
patient is not competent
Oncology physicians believe that there are situations,
where the principle of respect for autonomy does not
apply. This study shows that physicians avoid asking the
patient to make a decision if the patient is in a difficult sit-
uation, since it is not fair or just under these circumstances
to place stress on the patient. This means that the physi-
cian's decision about treatment depends on the physical
and psychological condition of the patient. Following
Beauchamp & Childress, this describes situations in which
the principle of respect for autonomy does not apply
because of the physical and psychological condition of
the patient. The patient is not competent, i.e. the patient
is not able to make autonomous decisions. Beauchamp &
Childress define competence to decide about treatment or
about participation in research the following way:
"Patients or subjects are competent to make a decision if
they have the capacity to understand the material infor-
mation, to make a judgement about the information in
light of their values, to intend a certain outcome, and to
communicate freely their wishes to care givers or investi-
gators" [16]. According to Beauchamp & Childress, when
the principle of respect for autonomy does not apply, the
principles of beneficence and nonmaleficence step in
[16].
Situations where the principle of respect for autonomy
does not apply can also be considered as justice situations:
it is not fair or just under the circumstances to ask the
patient in that specific situation to participate in research.
Basically, it is about inclusion criteria. But the case can
also be looked at from the point of view of keeping the
well-being of the patient in focus. According to the physi-
cian, it is too great a burden to put on the patient in that
specific situation to ask him/her to participate in research.
Following Beauchamp & Childress' theory, the physician
balances the principles of beneficence and nonmalefi-
cence.
Justice – fairness, waiting lists and limited resources
This study shows that the private biopharmaceutical com-
pany prioritises ethical evaluation of research because of
the investors. If the company behaves unethically, they
will be punished by the consumers and by the investors in
the long run. So it is important for the company to have
an ethical profile, since it pays off. For instance, the study
shows that the private biopharmaceutical company per-
forms clinical trials in developing countries and in order
to be fair and to benefit the human subjects, they are
assigned a lifetime of treatment. The motive of the com-
pany to help people living in developing countries has to
do with economics. This is in line with the fact that
although the individual researcher in the biopharmaceu-
tical company has the beneficence of the patient in focus
when planning new projects, the choice of the manage-
ment of the company to start up a new project has to do
with economics. This means that the motive of the private
company helping people in developing countries and in
carrying out ethical evaluation has to do with economics,
but all things considered it has good consequences. From
this we can see that the principle of justice proposed by
the company has utilitarian characteristics. Utilitarianism
is a theory that prescribes the quantitative maximisation
of good consequences for a population. It is a form of con-
sequentialism. The good to be maximised is usually hap-
piness, pleasure, or preference satisfaction. These
consequences generally have something to do with the
welfare of people.Philosophy, Ethics, and Humanities in Medicine 2007, 2:23 http://www.peh-med.com/content/2/1/23
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Oncology physicians working in a clinic at a public hospi-
tal are dissatisfied with management demands for effi-
ciency, that budgets and demands for efficiency do not fit
together, and that the waiting lists are too long. Oncology
physicians believe that they have too many patients to
treat per day in the out-patients' clinic, since there is a
limit to how many patients they can treat per day with
empathy. Furthermore, oncology physicians find that
resources are limited, they have too few instruments and
too little equipment compared to the number of patients
suffering from cancer and they want to treat as many
patients as possible in the best way. However, the physi-
cian does not consider that resources are limited when
deciding treatment for the individual patient. When
deciding the inclusion criteria for a clinical trial, physi-
cians firstly have the present patient in focus and consider
how this experiment can benefit this patient. Secondly,
the physician considers how this experiment can benefit
future patients. From this we see that the overall concept
of justice proposed by oncology physicians has utilitarian
characteristics, since they want to treat as many patients as
possible in the best way with the resources allocated.
However, we also see that the individual patient is not sac-
rificed for the benefit of future patients.
Just like oncology physicians, molecular biologists
employed at a public university find that resources are
limited, they think that a lot of time is spent on paper-
work, administration and fund-raising. They feel stressed
since they are under a constant pressure to apply for exter-
nal funding for research and the competition is hard. So
molecular biologists employed at a public university find
that public funding for research is limited and that they
are forced to apply for external funding which is time and
energy-consuming. This means that they reflect about
allocation, but they do not propose a specific theory of
allocation or justice.
As indicated above, the concept of justice proposed by the
private biopharmaceutical company and by oncology
physicians has utilitarian characteristics. However, the
respondents do not touch upon the principle of justice
reflected in the way health care resources are allocated in
Denmark as a whole. Beauchamp & Childress do describe
how the systems of health care financing and delivery in
Scandinavian countries are organised. They state that the
system in these countries primarily looks to egalitarian
justice, with utility as a secondary consideration [16].
Egalitarian theories emphasise "equal access to the goods
in life that every rational person values (often invoking
material criteria of need and equality)" [16]. Beauchamp
& Childress [16] describe the Scandinavian systems as
unified national systems, which in principle cover all citi-
zens without reference to age, health status, medical con-
dition or employment status. The justification for the
system is that only government can provide universal cov-
erage and cover increases in health care expenditures.
Every person gets national health care, pays no charges for
services, is free to choose a provider, and is eligible to
receive the services covered, which include long-term and
chronic care services. Physicians are free to work on a sal-
aried basis or to practise privately. Regional boards estab-
lish fees and no physician is allowed to charge the
government more than the amount set by the boards.
Among the controversial features of this system are the
elimination or near elimination of competitive aspects in
the financing system and the resulting disutility.
Beauchamp & Childress propose a principle of justice that
includes both utilitarian and egalitarian standards. They
write: "In particular, we have proposed that society recog-
nize an enforceable right to a decent minimum of health
care within a framework for allocation that incorporates
both utilitarian and egalitarian standards" [16]. This study
therefore indicates that the principle of justice proposed
by Beauchamp & Childress is applied at the level of indi-
vidual physicians, in the biopharmaceutical company,
and according to Beauchamp & Childress also at the level
of the system of health care allocation as a whole in Den-
mark.
Conclusion
This empirical study shows that the principle of benefi-
cence proposed by Beauchamp & Childress, which
requires the taking of action to help – by preventing harm,
removing harm and promoting good [16] – is at stake in
the daily work of oncology physicians employed in a
clinic and in the daily work of molecular biologists
employed in a private biopharmaceutical company, since
the motivation of both these groups is to help sick people.
Furthermore, according to this study, the principle of non-
maleficence of Beauchamp & Childress is at stake in the
daily work of each of the three groups of respondents.
However, there are differences with regard to the kinds of
nonmaleficence considerations in the different groups.
The nonmaleficence considerations of the two groups of
molecular biologists are related to the environment, to the
researchers' own health, to animal models, and only
implicitly to human subjects. In contrast, the nonmalefi-
cence considerations of oncology physicians have to do
with patients or human subjects.
The fact that molecular biologists investigate DNA and
cells in cultures, whereas physicians work with human
beings in a doctor-patient relationship might have the
effect that molecular biologists and oncology physicians
perceive or experience the principle of respect for the
autonomy of patients or human subjects in different ways.
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ciple of respect for autonomy, which says that autono-
mous actions should not be subjected to controlling
constraints by others, is reflected in the experience of both
oncology physicians and molecular biologists in their
daily work. But the positive obligation of the principle of
Beauchamp & Childress, which requires respectful treat-
ment in disclosing information, probing for and ensuring
understanding and voluntariness, and fostering autono-
mous decision-making is only reflected in the experience
of oncology physicians and not of molecular biologists. In
dialogue with the patient, physicians perform a medical
prognosis based on the patient's wishes and ideas, with
mutual understanding and respect.
There are situations in which the patient is not competent
and the principle of respect for autonomy does not apply.
According to Rendtorff & Kemp [30], this is where other
supplementary principles must be taken into account
such as respect for dignity, integrity and vulnerability to
protect the human person. Rendtorff & Kemp [30] accuse
the theory of Beauchamp & Childress of having too nar-
row a concept of the human person by regarding the prin-
ciple of respect for autonomy as the primary principle.
However, according to Beauchamp & Childress, the prin-
ciples of beneficence and nonmaleficence step in if the
patient is not competent [16]. Actually, this study shows
that the principles of beneficence and nonmaleficence
actually do step in when the patient is not competent and
the principle of respect for autonomy does not apply.
From the study we see, that molecular biologists
employed at a public university do not propose a specific
theory of justice. The principle of justice proposed by
oncology physicians and by the private biopharmaceuti-
cal company has utilitarian characteristics. Furthermore,
the health care system in Denmark primarily looks to
egalitarian justice, with utility as a secondary considera-
tion [16]. The principle of justice proposed by Beauchamp
& Childress includes both utilitarian and egalitarian
standards. This study therefore indicates that the principle
of justice of Beauchamp & Childress is applied both at the
level of the individual physician and the biopharmaceuti-
cal company and, according to Beauchamp & Childress, at
the level of the system of health care allocation as a whole
in Denmark.
In conclusion, this study shows that each of the four
bioethical principles of Beauchamp & Childress is
reflected in the daily work of oncology physicians and
molecular biologists and thereby indicates that the princi-
ples are applicable to the Danish biomedical setting. In
this study we have not simply systematically described the
ethical reasoning of oncology physicians and molecular
biologists. By taking an approach to bioethics in which we
combine elements from theory and practice, where empir-
ical research is integrated into the formulation of norma-
tive ethical principles, we believe that the conclusions of
this study might provide health care professionals and
biomedical researchers with normative principles that are
concordant with their biomedical practice and which have
normative implications.
Future perspectives
Beauchamp & Childress claim that their bioethical princi-
ples are part of a cross-cultural common morality [16],
but some of their critics state that the principle-based the-
ory is developed from a shared American morality and
mirrors certain aspects of American society, and that it
might for this reason alone be non-transferable to other
contexts and other societies [24]. Nonetheless, the find-
ings of this article indicate that the principles of respect for
autonomy, beneficence, nonmaleficence and justice are
transferable to Danish biomedical practice. Future per-
spectives of this study are to investigate biomedical prac-
tice in several different cultures, for instance Asian,
American and Southern European cultures, to test
whether Beauchamp & Childress' principles are cross-cul-
tural and thus have a universal perspective.
Appendix
Note 1: Following Tom L. Beauchamp & James F. Chil-
dress, we understand the term bioethical principles as
"general norms that leave considerable room for judg-
ment in many cases. They do not act as precise action
guides that inform us in each circumstance how to act in
the way that more detailed rules and judgments do" [16].
Note 2: The notion of 'coherence' is not well defined. Phi-
losophers agree that coherence is not only characterised
by consistency [38,39]. According to the Danish philoso-
pher, Klemens Kappel [39], coherence is characterised by
consistency, systematicity (a belief set should contain
explanatory relations), generality (a belief set should con-
tain general beliefs that cover a larger area rather than a
smaller one), and simplicity (general explanatory beliefs
should be few and simple rather than many and com-
plex).
Note 3: Our note. According to Rawls, a competent judge
possesses the following characteristics: Intelligence and
knowledge, intellectual virtues of reasonableness, an open
mind, and sympathetic knowledge of those human inter-
ests which give rise to the need to make a moral decision
[11].
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